Frontera Therapeutics
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Frontera Therapeutics
RECRUITINGEarly Phase 1NCT05874310
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
Sponsor: Frontera TherapeuticsEnrolling: 182 locations
X-Linked Retinitis Pigmentosa
RECRUITINGPhase 1 / Phase 2NCT06492850
Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa
The aim of this study was to evaluate the safety, tolerability, and efficacy of one-time subretinal injection of FT-002 in male subjects (8-45 years of age) with RPGR (Retinitis...
Sponsor: Frontera TherapeuticsEnrolling: 321 location
X-Linked Retinitis Pigmentosa (XLRP)